These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 26458953

  • 1. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y, Li J, Zhang Y, Wang F, Chen N, Chen H, Chen Y.
    J Exp Clin Cancer Res; 2015 Oct 12; 34():118. PubMed ID: 26458953
    [Abstract] [Full Text] [Related]

  • 2. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A, Katayama R, Oh-Hara T, Sato S, Okuno Y, Fujita N.
    Mol Cancer Ther; 2014 Dec 12; 13(12):2978-90. PubMed ID: 25313010
    [Abstract] [Full Text] [Related]

  • 3. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P.
    Clin Cancer Res; 2013 May 01; 19(9):2381-92. PubMed ID: 23532890
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
    Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N.
    Cancer Res; 2013 May 15; 73(10):3087-96. PubMed ID: 23598276
    [Abstract] [Full Text] [Related]

  • 5. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E, Labianca R.
    Expert Opin Investig Drugs; 2014 Nov 15; 23(11):1563-74. PubMed ID: 25307444
    [Abstract] [Full Text] [Related]

  • 6. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
    Lu S, Török HP, Gallmeier E, Kolligs FT, Rizzani A, Arena S, Göke B, Gerbes AL, De Toni EN.
    Oncotarget; 2015 Sep 08; 6(26):22167-78. PubMed ID: 26259250
    [Abstract] [Full Text] [Related]

  • 7. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
    Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA.
    Mol Oncol; 2015 Jan 08; 9(1):260-9. PubMed ID: 25226813
    [Abstract] [Full Text] [Related]

  • 8. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
    Yan J, Zhuang Q, Li Z, Xiong Y, He M, Kang C, Zhang Q, Han L, Liang E, Liu H, Ke P, Huang X.
    Eur J Pharmacol; 2021 May 05; 898():173975. PubMed ID: 33647258
    [Abstract] [Full Text] [Related]

  • 9. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.
    Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.
    Clin Cancer Res; 2017 Aug 01; 23(15):4364-4375. PubMed ID: 28246274
    [Abstract] [Full Text] [Related]

  • 10. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, Bian J, Chen Z, Yang Y.
    Cancer Lett; 2016 Sep 28; 380(1):134-43. PubMed ID: 27349166
    [Abstract] [Full Text] [Related]

  • 11. Tivantinib in hepatocellular carcinoma.
    Trojan J, Zeuzem S.
    Expert Opin Investig Drugs; 2013 Jan 28; 22(1):141-7. PubMed ID: 23167786
    [Abstract] [Full Text] [Related]

  • 12. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
    Kobayashi K, Higai K, Mukozu T, Matsui D, Amanuma M, Yoshimine N, Ogino Y, Matsui T, Wakui N, Shinohara M, Momiyama K, Daido Y, Nagai H, Igarashi Y.
    Biol Pharm Bull; 2020 Jan 28; 43(9):1421-1425. PubMed ID: 32879217
    [Abstract] [Full Text] [Related]

  • 13. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
    Yuan S, Gong Y, Chen R, Du J, Zhang H, Chen T.
    Biomed Pharmacother; 2020 Dec 28; 132():110867. PubMed ID: 33075668
    [Abstract] [Full Text] [Related]

  • 14. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V.
    Neoplasia; 2015 Mar 28; 17(3):289-300. PubMed ID: 25810013
    [Abstract] [Full Text] [Related]

  • 15. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K.
    Front Immunol; 2021 Mar 28; 12():731527. PubMed ID: 34804015
    [Abstract] [Full Text] [Related]

  • 16. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
    Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.
    Cell Death Dis; 2019 Mar 08; 10(3):231. PubMed ID: 30850583
    [Abstract] [Full Text] [Related]

  • 17. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 08; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 18. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C, Giglione P, Ferrari A, Reversi F, Liguigli W, Imarisio I, Ganini C.
    Expert Rev Anticancer Ther; 2015 Jun 08; 15(6):615-22. PubMed ID: 26035719
    [Abstract] [Full Text] [Related]

  • 19. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
    Xi WH, Yang LY, Cao ZY, Qian Y.
    Biochem Biophys Res Commun; 2015 Feb 20; 457(4):723-9. PubMed ID: 25623532
    [Abstract] [Full Text] [Related]

  • 20. A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells.
    Ho CT, Chang YJ, Yang LX, Wei PL, Liu TZ, Liu JJ.
    PLoS One; 2015 Feb 20; 10(9):e0136340. PubMed ID: 26355599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.